ML141
Based on 35 publication(s) in Google Scholar
ML141 (CID-2950007) is a potent, allosteric, selective and reversible non-competitive inhibitor of Cdc42 GTPase. ML141 inhibits Cdc42 wild type and Cdc42 Q61L mutant with EC50s of 2.1 and 2.6 μM, respectively. ML141 shows low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 do not show cytotoxicity in multiple cell lines.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.96%
- CAS No.: 71203-35-5
- Formule: C22H21N3O3S
- Masse moléculaire:407.49
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) ML141
More- Immunity. 2025 Nov 11;58(11):2670-2684.e10. [Abstract]
- Sci Bull. 2023 Oct 15;68(19):2210-2224. [Abstract]
- Adv Funct Mater. 2024 May 1.
- Nat Commun. 2025 Feb 4;16(1):1327. [Abstract]
- Nat Commun. 2023 Jan 30;14(1):478. [Abstract]
- Nat Commun. 2022 Nov 11;13(1):6840. [Abstract]
- Genes Dis. 2026 Jan 21.
- Adv Sci (Weinh). 2025 Dec 27:e13632. [Abstract]
- Cell Death Dis. 2026 Jun 16. [Abstract]
- Cell Death Dis. 2026 Mar 25;17(1):377. [Abstract]
- Angiogenesis. 2025 Aug 20;28(4):44. [Abstract]
- Br J Cancer. 2023 Jan;128(1):148-159. [Abstract]
- Stem Cell Res Ther. 2021 Jan 22;12(1):76. [Abstract]
- Cell Rep. 2025 Dec 6;44(12):116649. [Abstract]
- Cell Rep. 2025 Mar 5;44(3):115397. [Abstract]
- Int J Oncol. 2022 Oct;61(4):129. [Abstract]
- Hum Reprod. 2024 Dec 1;39(12):2768-2784. [Abstract]
- Cell Biosci. 2023 Jan 20;13(1):13. [Abstract]
- Int Endod J. 2026 Jun 2. [Abstract]
- Glia. 2023 Aug;71(8):1985-2004. [Abstract]
- Sci Rep. 2020 Aug 25;10(1):14151. [Abstract]
- Comput Struct Biotechnol J. 2021:19:1933-1943. [Abstract]
- J Virol. 2025 Apr 15;99(4):e0176124. [Abstract]
- PLoS Genet. 2022 Jun 27;18(6):e1010292. [Abstract]
- Cell Mol Bioeng. 2022 Oct 6;15(6):599-609. [Abstract]
- Vet Microbiol. 2022 Aug:271:109488. [Abstract]
- Virology. 2024 Dec:600:110233. [Abstract]
- Biochem Biophys Res Commun. 2019 Oct 29;519(1):134-140. [Abstract]
- Oncol Lett. 2021 Nov;22(5):754. [Abstract]
- Res Sq. 2026 Apr 26.
- bioRxiv. 2025 January 14.
- bioRxiv. 2024 October 12.
- medRxiv. 2023 Nov 11.
- bioRxiv. 2023 Oct 16.
- Indian J Pharm Sci. 2021 Jun.
Customer Validation & Images
-
IHC
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
-
IF
Activité biologique
ML141 (CID-2950007) is not cytotoxic in either cell line at doses of 0.1-3 μM after treatment for 4 days. OVCA429 cells were insensitive to 10 μM compound, whereas some cytotoxicity was observed in SKOV3ip cells at this concentration after a 4-day treatment, although it did not reach statistical significance. ML141 is not cytotoxic toward Swiss 3T3 or Vero E6 cells up to 10 μM for 24 and 48 h, respectively[1].
ML141 inhibits 3T3 fibroblast filopodia formation and inhibits ovarian cancer cell migration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57Bl/6J mice[3]
-
Dosage:10 µM
-
Administration:Intracerebroventricular injection
-
Result:Increased anxiety in mice.
Chemical Information
-
CAS No. 71203-35-5
-
Appearance Solid
-
Masse moléculaire 407.49
-
Formule C22H21N3O3S
-
Color White to off-white
-
SMILES
O=S(C1=CC=C(N2N=C(C3=CC=CC=C3)CC2C4=CC=C(OC)C=C4)C=C1)(N)=O
-
Synonyms
CID-2950007
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (35)
-
Journal Impact Factor
-
Most Recent
-
Immunity
Membrane integrity changes upon viral infection activate sphingomyelinase SMPDL3B to restrict cGAS-STING signaling via cGAMP degradation. [Abstract]2025 Nov 11;58(11):2670-2684.e10. PMID: 41175872 -
Sci Bull
Single particle tracking reveals SARS-CoV-2 regulating and utilizing dynamic filopodia for viral invasion. [Abstract]2023 Oct 15;68(19):2210-2224. PMID: 37661543 -
-
Nat Commun
Harnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors via the TRAIN mechanism. [Abstract]2025 Feb 4;16(1):1327. PMID: 39900573 -
Nat Commun
Salmonella effector SopB reorganizes cytoskeletal vimentin to maintain replication vacuoles for efficient infection. [Abstract]2023 Jan 30;14(1):478. PMID: 36717589
ML141 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Jan 30;14(1):478. [Abstract]
Treatment with Cdc42 inhibitor ML141 (5 µM) disassembled SCVs giving rise to increased proportion of dispersive SCV in wild-type, but not in vimentin KO cells.
-
Nat Commun
pTINCR microprotein promotes epithelial differentiation and suppresses tumor growth through CDC42 SUMOylation and activation. [Abstract]2022 Nov 11;13(1):6840. PMID: 36369429 -
-
Adv Sci (Weinh)
Low YTHDC1 Expression Upregulates FSCN1 to Promote Nuclear F-Actin Formation and Facilitate Double-strand DNA Breaks Repair in TMZ-Resistant Glioblastoma. [Abstract]2025 Dec 27:e13632. PMID: 41454694 -
Cell Death Dis
Pictilisib and nutrient stress synergize to induce methuosis via PI(4,5)P2-dependent macropinocytic dysregulation in cancer cells. [Abstract]2026 Jun 16. PMID: 42303628 -
Cell Death Dis
cGAS-STING/HMGB1-mediated senescence induced by LRRK2 accelerates cartilage degeneration in osteoarthritis. [Abstract]2026 Mar 25;17(1):377. PMID: 41881967 -
Angiogenesis
MY-1 promotes angiogenesis in the ischemic hindlimbs by regulating the stability of CDC42 via PSMD14. [Abstract]2025 Aug 20;28(4):44. PMID: 40833626
ML141 purchased from MedChemExpress. Usage Cited in: Angiogenesis. 2025 Aug 20;28(4):44. [Abstract]
In the MY-1 group, cells at the wound edge extended filopodia in the direction of migration, while in the presence of ML141, filopodia formation was suppressed, and MY-1 could not reverse the inhibitory effect of ML141 (10 μM).
ML141 purchased from MedChemExpress. Usage Cited in: Angiogenesis. 2025 Aug 20;28(4):44. [Abstract]
Treatment with ML141 reduced the primary tube length, node count, network formation in the tube formation assay and the number of migrated cells in the Transwell assay. Similarly, MY-1 could not reverse the inhibitory effect of ML141(10 μM).
-
Br J Cancer
2023 Jan;128(1):148-159. PMID: 36319849 -
Stem Cell Res Ther
Exosomes derived from stem cells from apical papilla promote craniofacial soft tissue regeneration by enhancing Cdc42-mediated vascularization. [Abstract]2021 Jan 22;12(1):76. PMID: 33482924 -
Cell Rep
Context-dependent inhibitory roles of RhoA in 3D invasive cell migration within the extracellular matrix. [Abstract]2025 Dec 6;44(12):116649. PMID: 41359424 -
Cell Rep
ENKD1 modulates innate immune responses through enhanced geranylgeranyl pyrophosphate synthase activity. [Abstract]2025 Mar 5;44(3):115397. PMID: 40048432 -
Int J Oncol
LIS1 interacts with CLIP170 to promote tumor growth and metastasis via the Cdc42 signaling pathway in salivary gland adenoid cystic carcinoma. [Abstract]2022 Oct;61(4):129. PMID: 36102310 -
Hum Reprod
CDC42 deficiency leads to endometrial stromal cell senescence in recurrent implantation failure. [Abstract]2024 Dec 1;39(12):2768-2784. PMID: 39487595
ML141 purchased from MedChemExpress. Usage Cited in: Hum Reprod. 2024 Dec 1;39(12):2768-2784. [Abstract]
ML141 (10 μM)-treated primary EnSCs remained spindle-shaped fibroblast-like cells after decidualization stimulation, without an obvious change in cell size
ML141 purchased from MedChemExpress. Usage Cited in: Hum Reprod. 2024 Dec 1;39(12):2768-2784. [Abstract]
ML141 (10μM) treatment hindered the upregulation of sST2 without affecting the secretion of CLU.
-
Cell Biosci
Hypofucosylation of Unc5b regulated by Fut8 enhances macrophage emigration and prevents atherosclerosis. [Abstract]2023 Jan 20;13(1):13. PMID: 36670464 -
Int Endod J
2026 Jun 2. PMID: 42227345 -
Glia
Celsr2-mediated morphological polarization and functional phenotype of reactive astrocytes in neural repair. [Abstract]2023 Aug;71(8):1985-2004. PMID: 37186402 -
Sci Rep
TRPV4 activates the Cdc42/N-wasp pathway to promote glioblastoma invasion by altering cellular protrusions. [Abstract]2020 Aug 25;10(1):14151. PMID: 32843668 -
Comput Struct Biotechnol J
Dependence of SARS-CoV-2 infection on cholesterol-rich lipid raft and endosomal acidification. [Abstract]2021:19:1933-1943. PMID: 33850607 -
J Virol
In vivo investigation of PEDV transmission via nasal infection: mechanisms of CD4+ T-cell-mediated intestinal infection. [Abstract]2025 Apr 15;99(4):e0176124. PMID: 40094365 -
PLoS Genet
Juvenile hormone promotes paracellular transport of yolk proteins via remodeling zonula adherens at tricellular junctions in the follicular epithelium. [Abstract]2022 Jun 27;18(6):e1010292. PMID: 35759519 -
Cell Mol Bioeng
Light Activates Cdc42-Mediated Needle-Shaped Filopodia Formation via the Integration of Small GTPases. [Abstract]2022 Oct 6;15(6):599-609. PMID: 36531863 -
Vet Microbiol
Epidermal growth factor receptor (EGFR) promotes uptake of bovine parainfluenza virus type 3 into MDBK cells. [Abstract]2022 Aug:271:109488. PMID: 35691094 -
Virology
2024 Dec:600:110233. PMID: 39255726 -
Biochem Biophys Res Commun
Cdc42-mediated supracellular cytoskeleton induced cancer cell migration under low shear stress. [Abstract]2019 Oct 29;519(1):134-140. PMID: 31477271 -
Oncol Lett
EGFR and ERK activation resists flavonoid quercetin-induced anticancer activities in human cervical cancer cells in vitro. [Abstract]2021 Nov;22(5):754. PMID: 34539858 -
-
-
-
-
-
Solvant et solubilité
DMSO : 100 mg/mL (245.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (5.10 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.10 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Hong L, et al. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem. 2013 Mar 22;288(12):8531-43. [Content Brief]
[2]. Surviladze Z, et al. A Potent and Selective Inhibitor of Cdc42 GTPase. Probe Reports from the NIH Molecular Libraries Program [Content Brief]
[3]. Hanin G, et al. Competing targets of microRNA-608 affect anxiety and hypertension. Hum Mol Genet. 2014 Sep 1;23(17):4569-80. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4540 mL | 12.2702 mL | 24.5405 mL | 61.3512 mL |
| 5 mM | 0.4908 mL | 2.4540 mL | 4.9081 mL | 12.2702 mL | |
| 10 mM | 0.2454 mL | 1.2270 mL | 2.4540 mL | 6.1351 mL | |
| 15 mM | 0.1636 mL | 0.8180 mL | 1.6360 mL | 4.0901 mL | |
| 20 mM | 0.1227 mL | 0.6135 mL | 1.2270 mL | 3.0676 mL | |
| 25 mM | 0.0982 mL | 0.4908 mL | 0.9816 mL | 2.4540 mL | |
| 30 mM | 0.0818 mL | 0.4090 mL | 0.8180 mL | 2.0450 mL | |
| 40 mM | 0.0614 mL | 0.3068 mL | 0.6135 mL | 1.5338 mL | |
| 50 mM | 0.0491 mL | 0.2454 mL | 0.4908 mL | 1.2270 mL | |
| 60 mM | 0.0409 mL | 0.2045 mL | 0.4090 mL | 1.0225 mL | |
| 80 mM | 0.0307 mL | 0.1534 mL | 0.3068 mL | 0.7669 mL | |
| 100 mM | 0.0245 mL | 0.1227 mL | 0.2454 mL | 0.6135 mL |
ML141 Related Classifications
HY-12755 Related Classifications
Powered by Bioz